Medical Research Finder

Loading…

© 2025 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Non-alcoholic fatty liver disease (NAFLD) & Drugs/Treatments

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

There are no drugs available at present to treat NAFLD
Chen et al. 2020l

Currently, bariatric surgery is a long-term effective therapy to prevent the progression of NAFLD and other manifestations of metabolic syndrome , such as obesity and type 2 diabetes .
Chalasani et al. 2018 Hepatology 67: 328-357
Syn et al. 2021 Lancet 397: 1830-1841

The ultimate goal in NAFLD treatment is prevention of mortality and progression to cirrhosis and HCC
(Suk & Kim 2019 Expert Review of Gastroenterology & Hepatology 13: 193-204)

There are no pharmacological effective treatments available yet for NAFLD.
Koopman et al. 2019 Aliment Pharmacol Ther. 50(6): 628-639

Pharmacological interventions include vitamin D and E, polyunsaturated fatty acids (PUFAs), [metformin](brain://QfdJc…

References (Sources)

Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment
Che et al. 2022f Front Endocrinol (Lausanne) 13:1002916
Review
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges
Alkhouri 2020
Non-alcoholic fatty liver disease: the diagnosis and management
Abd El-Kader & El-Den Ashmawy 2015 World J Hepatol 7: 846-58
Review
PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Cherubini et al. 2021 Expert Opinion on Therapeutic Targets 25(12): 1033-1043
Review
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease
Koopman et al. 2019 Aliment Pharmacol Ther. 50(6): 628-639
Review
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Chalasani et al. 2018 Hepatology 67: 328-357
Review
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh et al. 2017a World J Gastroenterol. 23(36): 6549-6570

AI Chat

12/16/2025

Chat with our artificial intelligence: